Immutep Limited
NASDAQ:IMMPBiotechnology
+$0.00 today
- Market cap
- $55.01M
- Beta
- 2.24
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$0.06
Volume 3.10M
Average 13.46M
IMMP Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Immutep LimitedNASDAQ: IMMP
Capital Expenditures · Q2 FY2026 · quarter ended Dec 2025
Capital expenditures grows 690.9% year over year
Q2 FY2026 capital expenditures of A$90.96K (cash outflow) rose 690.9% year over year. Over 3 fiscal years it compounded at +25.9% a year.
Context
- Capital expenditures amounted to 0.9% of revenue in FY2025, down 23.4 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
AUD · from the cash flow
- Latest · FY2025
- (45.77K) AUD
- Year-over-year change
- +95.1%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (45.77K) | +95.1% |
| FY2024 | 2024-06-30 | (932.37K) | -1883.8% |
| FY2023 | 2023-06-30 | (47K) | -105.1% |
| FY2022 | 2022-06-30 | (22.91K) | -46.9% |
| FY2021 | 2021-06-30 | (15.6K) | — |
Capital Expenditures vs competitors
How IMMP compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -95.1% is the 9th highest of 10, against a peer median of -14.8%.
- Capital expenditures amounts to 0.9% of revenue for IMMP, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.33M USD | +958.6% | -4.7% | — | |
| LTM Mar 2026 | $1.26M USD | +10391.7% | -23.2% | — | |
| LTM Mar 2026 | €955.79K EUR | +5.0% | +11.4% | 7.1% | |
| LTM Mar 2026 | $783K USD | -14.8% | +13.7% | 0.4% | |
| LTM Mar 2026 | $585K USD | -91.7% | -47.2% | 1.5% | |
| LTM Mar 2026 | $444K USD | -79.7% | -20.6% | — | |
| LTM Mar 2026 | $296K USD | -62.3% | -57.9% | — | |
| LTM Mar 2026 | $59K USD | +101.7% | -28.8% | 1.0% | |
| FY2025 | A$45.77K AUD | -95.1% | +25.9% | 0.9% | |
| LTM Mar 2026 | $3K USD | — | — | — | |
| LTM Mar 2026 | $1.52K USD | -99.5% | +15.4% | 0.3% | |
| Peer median (excluding IMMP) | — | -14.8% | -20.6% | 1.0% | |
Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (29.9M) | (32.21M) | (39.9M) | (42.72M) | (61.43M) |
| Depreciation & Amortization | 2.07M | 2.06M | 2.06M | 2.26M | 2.39M |
| Deferred Income Tax | (7.29M) | 0 | (4.99M) | 0 | 0 |
| Stock-Based Compensation | 1.7M | 1.49M | 2M | 1.8M | 1.16M |
| Change in Working Capital | (1.99M) | (1.56M) | 764.6K | 3.46M | (8.54M) |
| Accounts Receivables | (2.83M) | (2.25M) | (1.61M) | 601.77K | (2.52M) |
| Inventory | 0 | 813.92K | 0 | 0 | 0 |
| Accounts Payables | 1.38M | 1.44M | 3.27M | 0 | 0 |
| Other Working Capital | (543.42K) | (1.56M) | (900.11K) | 2.86M | (6.02M) |
| Other Non-Cash Items | 17.77M | (8.04K) | 4.17M | 379.87K | 4.37M |
| Operating Cash Flow | (17.64M) | (30.23M) | (35.88M) | (34.82M) | (62.05M) |
| Capital Expenditures | (15.6K) | (22.91K) | (47K) | (932.37K) | (45.77K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (20.09M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 16K | (903.15K) | (38.49M) |
| Investing Cash Flow | (15.6K) | (22.91K) | (31K) | (21.02M) | (38.53M) |
| Debt Repayment | (214.38K) | (222.54K) | (211.97K) | (226.49K) | (270.67K) |
| Common Stock Issued | 43.31M | 52.98M | 80.08M | 100.24M | (164.79K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.59M | (2.43M) | (3.83M) | (4.83M) | (254.46K) |
| Financing Cash Flow | 52.68M | 50.33M | 76.04M | 95.18M | (525.12K) |
| Effect of Forex Changes | (752.84K) | (671.04K) | 3.3M | (967.73K) | 6.73M |
| Net Change in Cash | 34.27M | 19.4M | 43.42M | 38.37M | (94.38M) |
| Free Cash Flow | (17.66M) | (30.25M) | (35.93M) | (35.75M) | (62.1M) |
Immutep Limited
NASDAQ:IMMP
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.